Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Niox Group flags solid revenue jump in 2023

(Sharecast News) - Medical device company Niox Group said in a trading update on Thursday that it experienced substantial revenue growth in 2023, with a reported increase of 18% to £36.8m. The AIM-traded firm said that on a constant currency basis, revenue growth was even more robust, standing at 22%.

It noted the majority of its sales are not invoiced in sterling, leading to revenue fluctuations influenced by exchange rates.

Clinical revenue, a significant portion of its earnings, increased by 24% to £32.6m, and on a constant currency basis, the growth amounted to 29%.

However, research revenues declined 18% to £4.2m, or by 14% when considering constant exchange rates.

The company reported an improvement in gross margins, with an increase from 71% in 2022 to 72% in 2023.

Recurring test kit revenues for the clinical business remained a significant contributor, representing 92% of clinical sales.

Adjusted EBITDA for the group reached £11.4m in 2023, compared to £7.3m in 2022, aligning with the consensus market expectations, which were revised upwards twice during the year.

Niox said it ended the year with a net cash balance of £19.9m, slightly up from £19.4m at the end of 2022.

The company's continuing activities generated £11m of operating cash flow during the year.

Discontinued activities resulted in a cash outflow of £2m, and the firm paid a special dividend of £10.5m and received $3.5m from Beyond Air as part of a relevant settlement agreement.

"I am pleased to report continued strong growth in revenues and profits which were driven by our core clinical business," said executive chairman Ian Johnson.

"All three geographic areas generated good growth in the year.

"Our manufacturing partner also started work on the development of the next generation Niox Pro device, which is expected to be launched in 2025."

Johnson said that during 2024, management's focus was on growing revenues in the US, expanding into new healthcare professional channels, and developing a product for home-use.

"The board believes that the company's robust business model will continue to deliver profitable growth and drive further shareholder value."

Niox said it would release its preliminary results for the year ended 31 December on 26 March.

At 1439 GMT, shares in Niox Group were down 3.94% at 60.52p.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Frontier IP appoints new finance chief
(Sharecast News) - Intellectual property commercialisation specialist Frontier IP announced the appointment of Jo Stent as its new chief financial officer on Friday, effective from 22 April.
Directa Plus asphalt technology laid at Imola Circuit
(Sharecast News) - Graphene nanoplatelet specialist Directa Plus announced on Friday that 'GiPave', an asphalt solution incorporating graphene and recycled plastics, was being installed at the Imola Circuit ahead of the Emilia-Romagna Grand Prix in May.
Huddled Group buys Food Circle for £0.3m
(Sharecast News) - E-commerce investor Huddled Group announced the acquisition of online retailer Food Circle Supermarket on Friday, for total consideration of up to £0.3m.
Bens Creek shares fall as it moves mine into care and maintenance
(Sharecast News) - Shares in North American metallurgical coal miner Bens Creek were sliding on Friday afternoon, after the company issued an update on its operations and working capital position, confirming that its West Virginia mine was moving into care and maintenance.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.